Coronado Biosciences, Inc. (NASDAQ:CNDO)

CAPS Rating: 2 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar Kvedarna (99.51) Submitted: 4/9/2014 12:47:22 PM : Outperform Start Price: $1.80 CNDO Score: +8.70

In a mood to get more risk on and adopted a number of ZZZZZman's most recent picks in biotech space

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 4/8/2014 3:38:59 PM : Outperform Start Price: $1.73 CNDO Score: +13.01

For CAPS purposes, I can green thumb Coronado despite the ugly decline in share price since the hysterical bubble peak of 3.2 in January. In real life, I would probably be a little more judicious although it would be quite interesting to see the gap fill all the way back to the 1.3 low from October. The current market cap is 76M and cash is 100M, but the short position is still 23%. A lot of people clearly think this company is pure, unadulterated garbage and after the pig poop worm egg debacle it's hard to disagree. Nevertheless, interesting things do happen to stocks where the market cap is well below cash so I'll be keeping an eye on Coronado for an irrational spike on new pie-in-the-sky PR.

Recs

0
Member Avatar JavaChipFool (59.67) Submitted: 2/5/2014 3:22:21 PM : Outperform Start Price: $2.45 CNDO Score: -28.75

Biotech gamble, down but not out

Recs

0
Member Avatar strima (28.37) Submitted: 11/22/2013 4:09:41 PM : Outperform Start Price: $1.46 CNDO Score: +33.03

net net

Recs

0
Member Avatar fatmoneyrz (97.99) Submitted: 10/14/2013 2:19:27 PM : Outperform Start Price: $2.10 CNDO Score: -17.54

Nice entry on nice little biotech with a solid pipeline and solid cash position.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $10.02 CNDO Score: +97.67

Biotech. Big losses. Selling tons of stock.

Recs

0
Member Avatar dwhit110 (< 20) Submitted: 7/15/2013 12:22:21 PM : Outperform Start Price: $8.63 CNDO Score: -95.01

The company has a smart and experienced executive team with past pharma experiencing getting drugs from the trial to FDA approved stage.

It's all a question of if their innovative solutions work as they're supposed to.

Recs

1
Member Avatar jcarnoldsf (21.89) Submitted: 1/25/2012 6:12:22 PM : Outperform Start Price: $6.18 CNDO Score: -122.62

This young biotech has a top-notch management team and an exciting roster of drugs entering final stage testing. The drugs are targeting autoimmune diseases and cancer. The most novel is an approach using parasites to activate the immune system. Has potential to be a big winner - buy now while it's still cheap!

Results 1 - 8 of 8

Featured Broker Partners


Advertisement